Radiation therapy and sorafenib: Clinical data and rationale for the combination in metastatic renal cell carcinoma

摘要: Sorafenib, an inhibitor of multiple tyrosine kinases including vascular endothelial growth factor receptor and Raf/mitogen-activated protein kinase, increases progression-free survival in metastatic renal cell carcinoma (RCC) compared with placebo. The efficacy toxicity combined sorafenib radiation therapy (RT) the treatment RCC are unknown. This is a retrospective report 3 consecutive patients or locally recurrent treated palliative RT while undergoing therapy. All experienced disease progression on remained drug without dose reduction during plus regimen. They were followed for response by clinical history, physical examination, contrast-enhanced computed tomography scans. Soon after completion RT, all complete pain relief need narcotic medication. Posttreatment imaging revealed partial > 50% regression tumor patients. None reported significant acute late side effects at follow-up 3, 6, 8 months sorafenib. In this report, combination was well tolerated resulted excellent radiologic responses. promising requires further study.